A A QUYYUMI, T CRAKE, C M WRIGHT, L J MOCKUS, K M FOX From the National Heart Hospital, London SUMMARY The role of medical treatment of patients who had resting nocturnal angina as well as exertional angina was investigated. The effects of atenolol 100 mg a day, nifedipine 20mg three times a day, and isosorbide mononitrate 40mg twice a day were investigated in a double blind, triple dummy randomised study. Nine patients with coronary artery disease, early positive exercise tests, and transient daytime and nocturnal ambulatory ST segment changes were initially assessed off all antianginal medication. They were then treated with each drug for three five day periods. Angina diaries were reviewed and maximal treadmill exercise tests and 48 hour ambulatory ST segment monitoring were performed at the end of each treatment period. Resting and exercise heart rate and blood pressure were significantly lower on atenolol than on either isosorbide mononitrate or nifedipine. The duration of exercise to 1 mm ST segment depression was significantly greater on atenolol than on isosorbide mononitrate. Only one patient had an improvement in exercise tolerance on nifedipine that was greater than the improvement on atenolol; this patient had single vessel disease. The total number and duration of episodes of ST segment change during ambulatory monitoring were significantly lower with atenolol than on either isosorbide mononitrate or nifedipine. Nocturnal ST segment changes were abolished in six patients on atenolol, in six patients on nifedipine, and in five patients on isosorbide mononitrate. When nocturnal ST segment changes occurred, their frequency was reduced with all three drugs. Pain was abolished in four patients on atenolol and pain relief was significantly better on atenolol than on isosorbide mononitrate. There was no significant difference in pain relief between isosorbide mononitrate and nifedipine.
Thus ,B receptor blockade with atenolol was the most effective means of reducing myocardial ischaemia both during exercise and at rest at night without causing deterioration in any patient. Nocturnal Atenolol was given in a daily dose of 100mg, isosorbide mononitrate 40 mg twice a day, and nifedipine was given three times at day at a dose of 10mg for two days and 20mg three times a day for three days to overcome the problems that occasionally arise with the higher dose of nifedipine.9 Throughout the various treatment periods, patients used sublingual nitroglycerin tablets to relieve pain. Six patients were assessed in hospital throughout the study and the other three patients had drug treatment periods at home. Patients were instructed to be mobile in and around the hospital or at home during the drug treatment periods. During the initial in hospital assessment period when all antianginal medication was discontinued, patients were advised not to undertake full activity in order to avoid frequent pain. The purpose of this part of the study was to identify patients with ST segment changes at night and at rest.
At the end of each treatment period, patients had ambulatory ST segment monitoring for 48 hours and kept angina diaries. Routine treadmill exercise tests were performed at the end of each five day treatment period. 
Results
During the initial assessment period all patients had reversible episodes of ST segment change-ST depression in eight and ST elevation in one-both during the day (mean (SD) 9 1 (3 5) episodes) and at rest at night (mean (SD) 2 1 (0 8)) during each 24 hour period (table 1) . Only a mean of 30% of episodes were accompanied by pain. One patient (case 2) could not tolerate isosorbide mononitrate because of headaches and nausea and another patient (case 7) could not tolerate nifedipine because headaches occurred even at a lower dose. In these two patients assessment was limited to only two drugs.
HEART RATE The heart rate throughout the day and night was significantly (p < 0 01) lower on atenolol than during the initial assessment period when patients were off all antianginal medication or when they were treated with nifedipine or isosorbide mononitrate. The heart rate on nifedipine and isosorbide mononitrate, however, was not significantly different either during the day or at night from that during the initial assessment period when all antianginal medication was discontinued. EXERCISE TEST Table 2 shows the duration of exercise to 1 mm ST segment depression during the different drug treatment periods. The mean duration of exercise to Heart rate (beats/min) 60 (13) 91 (14) 86 (12) (fig 1) . The mean workload achieved on nifedipine was 11 % less in the group as a whole than that achieved on atenolol. In two patients similar workloads were achieved befor ischaemia developed with the two drugs and on patient (case 2) reached a greater workload onedipine than on atenolol (fig 1) . In the seven ients in whom treatment with both nifedipine and isosorbide mononitrate can be compared there was no significant difference in exercise duration between these drugs. The mean resting heart rate was measured after the patient stood for two minutes before the exercise test. It was significantly lower on atenolol than on nifedipine (52%, p < 0 01) or on isosorbide mononitrate (43%, p < 0 01) (table 2). There was no difference in resting heart rate between nifedipine and isosorbide mononitrate (p > 0 05). There was no significant difference between the resting systolic and diastolic blood pressure during the different treatment periods. The heart rate and double product (heart rate x systolic blood pressure) were both significantly lower at the time of onset of 1 Medical treatment of patients with severe exertional and rest angina during each treatment period than during the initial assessment period when patients were off all antianginal medication. Pain was much less frequent on atenolol; four patients experienced no pain at all during the 48 hour monitoring period (fig 2) . Two patients became pain free on nifedipine and five had less pain on atenolol than on nifedipine. Two patients experienced more pain on atenolol than on nifedipine, although the number of painfree episodes of ST segment change and their duration were greater on nifedipine. In all patients the frequency of pain on atenolol was significantly less than that experienced on isosorbide mononitrate (65%, p < 0-01). There was no overall significant difference in pain frequency between isosorbide and nifedipine treatment periods (p > 0-05).
ADVERSE EFFECTS
None of the patients had more episodes of angina during any of the three treatment periods than during the initial assessment period when they were off all antianginal medication. One patient was intolerant of nifedipine and one of isosorbide mononitrate and they were assessed on two drugs only. We compared the efficacy of three established antianginal agents, which are currently widely used and have diverse modes of action, in the treatment of patients with exertional and nocturnal angina. We also assessed whether any agent was likely to cause deterioration of myocardial ischaemia experienced during normal daily activities or at night. Atenolol is a J31 selective receptor antagonist with no intrinsic sympathomimetic activity. '6 It has been shown to be an effective antianginal agent in placebo trials and as effective as other ,B receptor antagonists. 17 At a dose of 100 mg daily atenolol has significant negative chronotropic effects. In this study it reduced the heart rate and rate-pressure product not only at rest during the day and night but also on exercise. Thus, atenolol must have reduced myocardial oxygen consumption at rest and on exercise.
Discussion
Nifedipine Quyyumi, Crake, Wright, Mockus, Fox magnitude of episodes of myocardial ischaemia experienced. The effects of nifedipine and isosorbide mononitrate were not significantly different. The improvement on atenolol was not only striking with the daytime exertion related episodes but persisted during the episodes at rest at night. None of the patients experienced worsening of angina, either daytime or nocturnal, on atenolol.
Nocturnal ischaemia was improved on all three drugs; most patients did not experience nocturnal pain or ischaemia during any of the treatment periods. When it did recur, the frequency and duration of nocturnal ischaemia were less than during the initial assessment off all antianginal medication. This result indicates, firstly, that atenolol was effective not only in exertion related ischaemia but it also improved or abolished nocturnal resting angina without causing deterioration in any patient studied. Secondly, nocturnal resting ischaemia can also be treated effectively by the vasodilators nifedipine and isosorbide mononitrate which are, however, considerably less effective than atenolol for treating daytime exertion related angina. Finally, the mechanism of precipitation of nocturnal ischaemia in patients with severe coronary artery disease is likely to be multifactorial and a reduction of myocardial oxygen demand by 0 receptor antagonists is probably the most effective way of preventing ischaemia in this group of patients.
Most patients in this study had three vessel coronary artery disease, frequent angina, and greatly reduced exercise tolerance. In order to characterise the patients adequately, they were taken off all antianginal medication so that ambulatory monitoring could be performed. All patients had exertional angina and the purpose of this phase of the study was primarily to identify those patients who also had demonstrable nocturnal ischaemia. Patients were all admitted to hospital for this phase and advised not to undertake normal activity. This advice was likely to reduce exertion related ischaemia but would not be expected to influence resting or nocturnal ischaemia. For this reason, we have limited comparisons to the three double blinded treatment periods in this study because all these were performed in similar circumstances.
The only patient whose exercise response was most markedly improved with nifedipine had single vessel disease. This may be because this patient differed from the others in that an increase in vasomotor tone was an important mechanism in precipitating myocardial ischaemia-hence the good response to nifedipine and the relatively poor response to atenolol. Further investigations in this patient seemed to confirm this hypothesis as intravenous ergometrine produced pronounced localised coronary vasoconstriction.
Atenolol also increased the duration of exercise to ischaemia during conventional exercise testing more than isosorbide mononitrate did. Also only one patient reached a greater workload on nifedipine than on atenolol. As expected, the heart rate, blood pressure, and the rate-pressure product at rest were significantly lower on atenolol than on the two vasodilators. At the onset of 1 mm ST depression the heart rate and double product were lower on atenolol and remained significantly lower despite the duration of exercise being significantly longer on atenolol than on nifedipine or isosorbide mononitrate. This paradoxical reduction of the double product at peak exercise despite an improvement in exercise tolerance by ,B receptor antagonists has been reported before.27 28 The apparently detrimental effects of raising end diastolic filling pressure and coronary vascular resistance produced by 13 blockers may explain why the same rate-pressure product is not reached before ischaemia develops.29 30 Because all three drugs were beneficial in reducing the frequency of nocturnal angina and because their mechanisms of action are different, combination treatment of such patients may be appropriate.20 None the less, the overall effect of atenolol in this study was an improvement in exercise tolerance and a considerable reduction in myocardial ischaemia during the day and night. Thus 1 receptor blockade, far from being contraindicated, is in fact of benefit in patients who have severe exertional and nocturnal angina caused by severe coronary artery disease.
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